APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Tocilizumab Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Tocilizumab Biosimilars Industry Growth and Trends Forecast to 2032

Report ID 174041670127 December 202590 pages

Choose your research edition.

Industry ResearchTocilizumab Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Tocilizumab Biosimilars Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Tocilizumab Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tocilizumab Biosimilars Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Tocilizumab Biosimilars Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Tocilizumab Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Tocilizumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Tocilizumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tocilizumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tocilizumab Biosimilars include Biogen, Fresenius Kabi, Hetero, Bio-Thera Solutions, Hangzhou Bozhirui Biopharmaceutical and Zhuhai Livzon Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Tocilizumab Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Tocilizumab Biosimilars market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Tocilizumab Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Tocilizumab Biosimilars.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Tocilizumab Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Tocilizumab Biosimilars Market by Company

Biogen

Fresenius Kabi

Hetero

Bio-Thera Solutions

Hangzhou Bozhirui Biopharmaceutical

Zhuhai Livzon Biotechnology

Tocilizumab Biosimilars Segment by Type

Intravenous Infusion

Subcutaneous Injection

Tocilizumab Biosimilars Segment by Application

Giant Cell Arteritis

Rheumatoid Arthritis

Cytokine Release Syndrome

Juvenile Idiopathic Arthritis

Other

Tocilizumab Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tocilizumab Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tocilizumab Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tocilizumab Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tocilizumab Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Tocilizumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Intravenous Infusion Table 2. Major Company of Subcutaneous Injection Table 3. Global Tocilizumab Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Tocilizumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 5. Global Tocilizumab Biosimilars Sales Market Share in Volume by Type (2021-2026) Table 6. Global Tocilizumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 7. Global Tocilizumab Biosimilars Sales Market Share in Value by Type (2021-2026) Table 8. Global Tocilizumab Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 9. Global Tocilizumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 10. Global Tocilizumab Biosimilars Sales Market Share in Volume by Type (2027-2032) Table 11. Global Tocilizumab Biosimilars Sales by Type (2027-2032) & (US$ Million) Table 12. Global Tocilizumab Biosimilars Sales Market Share in Value by Type (2027-2032) Table 13. Global Tocilizumab Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 14. North America Tocilizumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 15. North America Tocilizumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Tocilizumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 17. Europe Tocilizumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Tocilizumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Tocilizumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Tocilizumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 21. Latin America Tocilizumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Tocilizumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Tocilizumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 24. Tocilizumab Biosimilars Industry Trends Table 25. Tocilizumab Biosimilars Industry Drivers Table 26. Tocilizumab Biosimilars Industry Opportunities and Challenges Table 27. Tocilizumab Biosimilars Industry Restraints Table 28. Global Tocilizumab Biosimilars Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Tocilizumab Biosimilars Revenue Market Share by Company (2021-2026) Table 30. Global Tocilizumab Biosimilars Sales by Company (2021-2026) & (K Units) Table 31. Global Tocilizumab Biosimilars Sales Share by Company (2021-2026) Table 32. Global Tocilizumab Biosimilars Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Tocilizumab Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Tocilizumab Biosimilars Major Company Production Sites and Headquarters Table 35. Global Tocilizumab Biosimilars Company, Product Type & Application Table 36. Global Tocilizumab Biosimilars Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Tocilizumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Tocilizumab Biosimilars Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Tocilizumab Biosimilars Sales by Region (2021-2026) & (K Units) Table 41. Global Tocilizumab Biosimilars Sales Market Share in Volume by Region (2021-2026) Table 42. Global Tocilizumab Biosimilars Sales by Region (2021-2026) & (US$ Million) Table 43. Global Tocilizumab Biosimilars Sales Market Share in Value by Region (2021-2026) Table 44. Global Tocilizumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Tocilizumab Biosimilars Sales by Region (2027-2032) & (K Units) Table 46. Global Tocilizumab Biosimilars Sales Market Share in Volume by Region (2027-2032) Table 47. Global Tocilizumab Biosimilars Sales by Region (2027-2032) & (US$ Million) Table 48. Global Tocilizumab Biosimilars Sales Market Share in Value by Region (2027-2032) Table 49. Global Tocilizumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Tocilizumab Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Tocilizumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 52. Global Tocilizumab Biosimilars Sales Market Share in Volume by Application (2021-2026) Table 53. Global Tocilizumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 54. Global Tocilizumab Biosimilars Sales Market Share in Value by Application (2021-2026) Table 55. Global Tocilizumab Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 56. Global Tocilizumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 57. Global Tocilizumab Biosimilars Sales Market Share in Volume by Application (2027-2032) Table 58. Global Tocilizumab Biosimilars Sales by Application (2027-2032) & (US$ Million) Table 59. Global Tocilizumab Biosimilars Sales Market Share in Value by Application (2027-2032) Table 60. Global Tocilizumab Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 61. North America Tocilizumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 62. North America Tocilizumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Tocilizumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 64. Europe Tocilizumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Tocilizumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Tocilizumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Tocilizumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 68. Latin America Tocilizumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Tocilizumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Tocilizumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 71. Biogen Company Information Table 72. Biogen Business Overview Table 73. Biogen Tocilizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Biogen Tocilizumab Biosimilars Product Portfolio Table 75. Biogen Recent Development Table 76. Fresenius Kabi Company Information Table 77. Fresenius Kabi Business Overview Table 78. Fresenius Kabi Tocilizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Fresenius Kabi Tocilizumab Biosimilars Product Portfolio Table 80. Fresenius Kabi Recent Development Table 81. Hetero Company Information Table 82. Hetero Business Overview Table 83. Hetero Tocilizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Hetero Tocilizumab Biosimilars Product Portfolio Table 85. Hetero Recent Development Table 86. Bio-Thera Solutions Company Information Table 87. Bio-Thera Solutions Business Overview Table 88. Bio-Thera Solutions Tocilizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bio-Thera Solutions Tocilizumab Biosimilars Product Portfolio Table 90. Bio-Thera Solutions Recent Development Table 91. Hangzhou Bozhirui Biopharmaceutical Company Information Table 92. Hangzhou Bozhirui Biopharmaceutical Business Overview Table 93. Hangzhou Bozhirui Biopharmaceutical Tocilizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Hangzhou Bozhirui Biopharmaceutical Tocilizumab Biosimilars Product Portfolio Table 95. Hangzhou Bozhirui Biopharmaceutical Recent Development Table 96. Zhuhai Livzon Biotechnology Company Information Table 97. Zhuhai Livzon Biotechnology Business Overview Table 98. Zhuhai Livzon Biotechnology Tocilizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Zhuhai Livzon Biotechnology Tocilizumab Biosimilars Product Portfolio Table 100. Zhuhai Livzon Biotechnology Recent Development Table 101. North America Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 102. North America Tocilizumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 103. North America Tocilizumab Biosimilars Sales Market Share by Country (2021-2026) Table 104. North America Tocilizumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 105. North America Tocilizumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 106. North America Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. North America Tocilizumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 108. North America Tocilizumab Biosimilars Market Share by Country (2021-2026) Table 109. North America Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. North America Tocilizumab Biosimilars Market Share Forecast by Country (2027-2032) Table 111. Europe Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. Europe Tocilizumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 113. Europe Tocilizumab Biosimilars Sales Market Share by Country (2021-2026) Table 114. Europe Tocilizumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 115. Europe Tocilizumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 116. Europe Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Europe Tocilizumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 118. Europe Tocilizumab Biosimilars Market Share by Country (2021-2026) Table 119. Europe Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Europe Tocilizumab Biosimilars Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific Tocilizumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 123. Asia-Pacific Tocilizumab Biosimilars Sales Market Share by Country (2021-2026) Table 124. Asia-Pacific Tocilizumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 125. Asia-Pacific Tocilizumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific Tocilizumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 128. Asia-Pacific Tocilizumab Biosimilars Market Share by Country (2021-2026) Table 129. Asia-Pacific Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Asia-Pacific Tocilizumab Biosimilars Market Share Forecast by Country (2027-2032) Table 131. Latin America Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Latin America Tocilizumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 133. Latin America Tocilizumab Biosimilars Sales Market Share by Country (2021-2026) Table 134. Latin America Tocilizumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 135. Latin America Tocilizumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 136. Latin America Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Latin America Tocilizumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 138. Latin America Tocilizumab Biosimilars Market Share by Country (2021-2026) Table 139. Latin America Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Latin America Tocilizumab Biosimilars Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa Tocilizumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 143. Middle East and Africa Tocilizumab Biosimilars Sales Market Share by Country (2021-2026) Table 144. Middle East and Africa Tocilizumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Tocilizumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa Tocilizumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 148. Middle East and Africa Tocilizumab Biosimilars Market Share by Country (2021-2026) Table 149. Middle East and Africa Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Middle East and Africa Tocilizumab Biosimilars Market Share Forecast by Country (2027-2032) Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. Tocilizumab Biosimilars Distributors List Table 154. Tocilizumab Biosimilars Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Tocilizumab Biosimilars Image Figure 2. Global Tocilizumab Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tocilizumab Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Tocilizumab Biosimilars Sales (2021-2032) & (K Units) Figure 5. Intravenous Infusion Image Figure 6. Global Intravenous Infusion Sales YoY Growth (2021-2032) & (K Units) Figure 7. Subcutaneous Injection Image Figure 8. Global Subcutaneous Injection Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Tocilizumab Biosimilars Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Tocilizumab Biosimilars Market Share by Type 2025 VS 2032 Figure 11. North America Tocilizumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 12. North America Tocilizumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 13. Europe Tocilizumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 14. Europe Tocilizumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Tocilizumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Tocilizumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 17. Latin America Tocilizumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Tocilizumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Tocilizumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Tocilizumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Tocilizumab Biosimilars Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Giant Cell Arteritis Image Figure 24. Global Giant Cell Arteritis Sales YoY Growth (2021-2032) & (K Units) Figure 25. Rheumatoid Arthritis Image Figure 26. Global Rheumatoid Arthritis Sales YoY Growth (2021-2032) & (K Units) Figure 27. Cytokine Release Syndrome Image Figure 28. Global Cytokine Release Syndrome Sales YoY Growth (2021-2032) & (K Units) Figure 29. Juvenile Idiopathic Arthritis Image Figure 30. Global Juvenile Idiopathic Arthritis Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Tocilizumab Biosimilars Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Tocilizumab Biosimilars Market Share by Application 2025 VS 2032 Figure 35. North America Tocilizumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 36. North America Tocilizumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 37. Europe Tocilizumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 38. Europe Tocilizumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Tocilizumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Tocilizumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 41. Latin America Tocilizumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Tocilizumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Tocilizumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Tocilizumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 45. North America Tocilizumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Tocilizumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Tocilizumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Tocilizumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Tocilizumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Tocilizumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Tocilizumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Tocilizumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Tocilizumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Tocilizumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Tocilizumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Tocilizumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Tocilizumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Tocilizumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Tocilizumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Tocilizumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Tocilizumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Tocilizumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Tocilizumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Tocilizumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Tocilizumab Biosimilars Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Tocilizumab Biosimilars Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous Infusion
  • Subcutaneous Injection
Applications
  • Giant Cell Arteritis
  • Rheumatoid Arthritis
  • Cytokine Release Syndrome
  • Juvenile Idiopathic Arthritis
  • Other
Companies covered
  • Biogen
  • Fresenius Kabi
  • Hetero
  • Bio-Thera Solutions
  • Hangzhou Bozhirui Biopharmaceutical
  • Zhuhai Livzon Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tocilizumab Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Tocilizumab Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Tocilizumab Biosimilars Market by Type
  6. 1.3.1 Intravenous Infusion
  7. 1.3.2 Subcutaneous Injection
  8. 1.4 Global Tocilizumab Biosimilars Market Size by Type
  9. 1.4.1 Global Tocilizumab Biosimilars Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Tocilizumab Biosimilars Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Tocilizumab Biosimilars Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Tocilizumab Biosimilars Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Tocilizumab Biosimilars Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Tocilizumab Biosimilars Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Tocilizumab Biosimilars Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Tocilizumab Biosimilars Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Tocilizumab Biosimilars Industry Trends
  2. 2.2 Tocilizumab Biosimilars Industry Drivers
  3. 2.3 Tocilizumab Biosimilars Industry Opportunities and Challenges
  4. 2.4 Tocilizumab Biosimilars Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Tocilizumab Biosimilars Revenue (2021-2026)
  2. 3.2 Global Top Players by Tocilizumab Biosimilars Sales (2021-2026)
  3. 3.3 Global Top Players by Tocilizumab Biosimilars Price (2021-2026)
  4. 3.4 Global Tocilizumab Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tocilizumab Biosimilars Major Company Production Sites & Headquarters
  6. 3.6 Global Tocilizumab Biosimilars Company, Product Type & Application
  7. 3.7 Global Tocilizumab Biosimilars Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tocilizumab Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tocilizumab Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tocilizumab Biosimilars Tier 1, Tier 2, and Tier 3
4 Tocilizumab Biosimilars Regional Status and Outlook
  1. 4.1 Global Tocilizumab Biosimilars Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Tocilizumab Biosimilars Historic Market Size by Region
  3. 4.2.1 Global Tocilizumab Biosimilars Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Tocilizumab Biosimilars Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Tocilizumab Biosimilars Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Tocilizumab Biosimilars Forecasted Market Size by Region
  7. 4.3.1 Global Tocilizumab Biosimilars Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Tocilizumab Biosimilars Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Tocilizumab Biosimilars Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Tocilizumab Biosimilars by Application
  1. 5.1 Tocilizumab Biosimilars Market by Application
  2. 5.1.1 Giant Cell Arteritis
  3. 5.1.2 Rheumatoid Arthritis
  4. 5.1.3 Cytokine Release Syndrome
  5. 5.1.4 Juvenile Idiopathic Arthritis
  6. 5.1.5 Other
  7. 5.2 Global Tocilizumab Biosimilars Market Size by Application
  8. 5.2.1 Global Tocilizumab Biosimilars Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Tocilizumab Biosimilars Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Tocilizumab Biosimilars Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Tocilizumab Biosimilars Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Tocilizumab Biosimilars Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Tocilizumab Biosimilars Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Tocilizumab Biosimilars Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Tocilizumab Biosimilars Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biogen
  2. 6.1.1 Biogen Company Information
  3. 6.1.2 Biogen Business Overview
  4. 6.1.3 Biogen Tocilizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biogen Tocilizumab Biosimilars Product Portfolio
  6. 6.1.5 Biogen Recent Developments
  7. 6.2 Fresenius Kabi
  8. 6.2.1 Fresenius Kabi Company Information
  9. 6.2.2 Fresenius Kabi Business Overview
  10. 6.2.3 Fresenius Kabi Tocilizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Fresenius Kabi Tocilizumab Biosimilars Product Portfolio
  12. 6.2.5 Fresenius Kabi Recent Developments
  13. 6.3 Hetero
  14. 6.3.1 Hetero Company Information
  15. 6.3.2 Hetero Business Overview
  16. 6.3.3 Hetero Tocilizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Hetero Tocilizumab Biosimilars Product Portfolio
  18. 6.3.5 Hetero Recent Developments
  19. 6.4 Bio-Thera Solutions
  20. 6.4.1 Bio-Thera Solutions Company Information
  21. 6.4.2 Bio-Thera Solutions Business Overview
  22. 6.4.3 Bio-Thera Solutions Tocilizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bio-Thera Solutions Tocilizumab Biosimilars Product Portfolio
  24. 6.4.5 Bio-Thera Solutions Recent Developments
  25. 6.5 Hangzhou Bozhirui Biopharmaceutical
  26. 6.5.1 Hangzhou Bozhirui Biopharmaceutical Company Information
  27. 6.5.2 Hangzhou Bozhirui Biopharmaceutical Business Overview
  28. 6.5.3 Hangzhou Bozhirui Biopharmaceutical Tocilizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Hangzhou Bozhirui Biopharmaceutical Tocilizumab Biosimilars Product Portfolio
  30. 6.5.5 Hangzhou Bozhirui Biopharmaceutical Recent Developments
  31. 6.6 Zhuhai Livzon Biotechnology
  32. 6.6.1 Zhuhai Livzon Biotechnology Company Information
  33. 6.6.2 Zhuhai Livzon Biotechnology Business Overview
  34. 6.6.3 Zhuhai Livzon Biotechnology Tocilizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Zhuhai Livzon Biotechnology Tocilizumab Biosimilars Product Portfolio
  36. 6.6.5 Zhuhai Livzon Biotechnology Recent Developments
7 North America by Country
  1. 7.1 North America Tocilizumab Biosimilars Sales by Country
  2. 7.1.1 North America Tocilizumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Tocilizumab Biosimilars Sales by Country (2021-2026)
  4. 7.1.3 North America Tocilizumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 7.2 North America Tocilizumab Biosimilars Market Size by Country
  6. 7.2.1 North America Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Tocilizumab Biosimilars Market Size by Country (2021-2026)
  8. 7.2.3 North America Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Tocilizumab Biosimilars Sales by Country
  2. 8.1.1 Europe Tocilizumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Tocilizumab Biosimilars Sales by Country (2021-2026)
  4. 8.1.3 Europe Tocilizumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Tocilizumab Biosimilars Market Size by Country
  6. 8.2.1 Europe Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Tocilizumab Biosimilars Market Size by Country (2021-2026)
  8. 8.2.3 Europe Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Tocilizumab Biosimilars Sales by Country
  2. 9.1.1 Asia-Pacific Tocilizumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Tocilizumab Biosimilars Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Tocilizumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Tocilizumab Biosimilars Market Size by Country
  6. 9.2.1 Asia-Pacific Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Tocilizumab Biosimilars Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Tocilizumab Biosimilars Sales by Country
  2. 10.1.1 South America Tocilizumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Tocilizumab Biosimilars Sales by Country (2021-2026)
  4. 10.1.3 South America Tocilizumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 10.2 South America Tocilizumab Biosimilars Market Size by Country
  6. 10.2.1 South America Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Tocilizumab Biosimilars Market Size by Country (2021-2026)
  8. 10.2.3 South America Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Tocilizumab Biosimilars Sales by Country
  2. 11.1.1 Middle East and Africa Tocilizumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Tocilizumab Biosimilars Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Tocilizumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Tocilizumab Biosimilars Market Size by Country
  6. 11.2.1 Middle East and Africa Tocilizumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Tocilizumab Biosimilars Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Tocilizumab Biosimilars Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Tocilizumab Biosimilars Value Chain Analysis
  2. 12.1.1 Tocilizumab Biosimilars Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Tocilizumab Biosimilars Production Mode & Process
  7. 12.2 Tocilizumab Biosimilars Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Tocilizumab Biosimilars Distributors
  10. 12.2.3 Tocilizumab Biosimilars Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst